Many individual biotech stocks have performed far worse. One bright side to all of that selling is that a handful of high-quality biotech stocks are currently trading for attractive prices.
Category: Regeneron Pharmaceuticals
Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today
Friday was another record day for the stock market, with the Dow climbing above 19,999 without quite making it the final point higher to 20,000 before falling back toward the end of the day. A mixed jobs report seemed to give investors the perfect balance between economic strength and weakness, and market sentiment remained positive to frustrate those who had anticipated a quick pullback from the post-election rally once 2017 began.
Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron Thursday to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.
Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.